Novel markers have the potential to dramatically change the decision making process in many branches of medicine, such as in early diagnosis of disease and in selecting patient specific treatments. Most biomarker tests are not perfect, and the costs of incorrect test results can be enormous, both in financial and human terms. To translate putative markers into standard medical care, rigorous evaluation is required. Prospective cohort studies are crucial for such evaluation as time to event carries more information about a marker's value on early detection and prognosis than a simple measure of disease status. However prospective biomarker evaluation is challenging. Until now there has been little guidance provided for statistical design and analysis of these studies.
We aim to develop novel statistical tools for designing and analyzing biomarker studies with time to event outcome. The proposal will emphasize three unique aspects in prospective biomarker evaluation. First, to fully characterize the diagnostic and prognostic potential of a novel marker, accuracy summaries must incorporate additional dimension of time.
In Aim 1 we propose time-dependent accuracy summaries and generalize the estimating methods which enable researchers to identify factors that influence marker performance, optimally combine several predictive factors and account for competing risk events. We also consider flexible procedures to quantify the updated predictive accuracy of longitudinal markers, and derive decision rules on the basis of risk, incorporating both cross-sectional and longitudinal marker information. Second, the ascertainment of marker information in a large cohort requires enormous resources. Cost-effective cohort sampling is therefore highly desirable.
In Aim 2 we will develop estimating and inference procedures for calculating accuracy summaries under cohort sampling designs and conduct simulation studies to shed light on the limitations and strengths of different sampling strategies under a variety of practical situations. Applications in cancer biomarker development provide a context for our research. Data from the Early Detection Research Network and from several large cohort studies will be analyzed. Programs and algorithms developed in this proposal will be made available to public.

Public Health Relevance

The research proposal addresses the pressing need for strong statistical input in cancer biomarker field, providing comprehensive statistical tools which will enable investigators to conduct valid and more powerful biomarker validation studies and to evaluate the diagnostic and prognostic potential of novel biomarkers. The research will demonstrate lasting usefulness as more biomarkers are developed and studied for potential impact on public health.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM085047-03
Application #
8120778
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Lyster, Peter
Project Start
2009-09-04
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2011
Total Cost
$324,952
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Diamandis, Eleftherios P; Eklund, Emma; Muytjens, Carla et al. (2017) Effect of age on serum prostate-specific antigen in women. Clin Chem Lab Med 55:e271-e272
Diamandis, Eleftherios P; Stanczyk, Frank Z; Wheeler, Sarah et al. (2017) Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clin Chem Lab Med 55:1789-1797
Zheng, Yingye; Brown, Marshall; Lok, Anna et al. (2017) IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS. Ann Appl Stat 11:638-654
Maziarz, Marlena; Heagerty, Patrick; Cai, Tianxi et al. (2017) On longitudinal prediction with time-to-event outcome: Comparison of modeling options. Biometrics 73:83-93
Macleod, Liam C; Ellis, William J; Newcomb, Lisa F et al. (2017) Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study. J Urol 197:1026-1033
Zhou, Qian M; Dai, Wei; Zheng, Yingye et al. (2017) Robust Dynamic Risk Prediction with Longitudinal Studies. Stat Theory Relat Fields 1:159-170
Payne, Rebecca; Yang, Ming; Zheng, Yingye et al. (2016) Robust risk prediction with biomarkers under two-phase stratified cohort design. Biometrics 72:1037-1045
Payne, Rebecca; Neykov, Matey; Jensen, Majken Karoline et al. (2016) Kernel machine testing for risk prediction with stratified case cohort studies. Biometrics 72:372-81
Leung, Felix; Bernardini, Marcus Q; Brown, Marshall D et al. (2016) Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer. Cancer Epidemiol Biomarkers Prev 25:1333-40
Zhao, Shanshan; Zheng, Yingye; Prentice, Ross L et al. (2015) Two-stage biomarker panel study and estimation allowing early termination for futility. Biostatistics 16:799-812

Showing the most recent 10 out of 25 publications